Home / Resource Library / Immunogenicity of a third dose of the BNT162b2 COVID‑19 vaccine in patients with CLL: effects on treatment selectionImmunogenicity of a third dose of the BNT162b2 COVID‑19 vaccine in patients with CLL: effects on treatment selection